Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

Core Viewpoint - Merus N.V. is a clinical-stage oncology company focused on developing innovative multispecific antibodies, with a presentation scheduled at Citi's 2025 Virtual Oncology Leadership Summit [1]. Company Overview - Merus N.V. specializes in full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics® [3]. - The company utilizes industry-standard processes for manufacturing Multiclonics®, which have demonstrated characteristics similar to conventional human monoclonal antibodies, including long half-life and low immunogenicity in preclinical and clinical studies [3]. Event Details - Bill Lundberg, M.D., President and CEO of Merus, will present at the summit on February 20, 2025, at 9:00 a.m. ET [1]. - The presentation will be available via webcast on the company's Investors page, with an archived version accessible for a limited time post-event [2].